| Oct 21 |
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
|
| Oct 16 |
Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds?
|
| Oct 16 |
Robert Mashal At Nuvation Bio Tops Up Holding By US$220k
|
| Oct 14 |
Is Nuvation Bio Inc. (NUVB) Hedge Funds’ Favorite Penny Stock?
|
| Oct 9 |
Growing Confidence in Nuvation Bio, Inc. (NUVB) as Hedge Fund Holdings Increase to 35
|
| Oct 7 |
Nuvation Bio names Philippe Sauvage CFO
|
| Oct 7 |
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
|
| Oct 2 |
Navigating Legal Uncertainty: Nuvation Bio Inc.’s Chinese Operations and the Shifting Landscape of China’s Civil Law System
|
| Sep 14 |
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
|
| Sep 9 |
Nuvation Bio to Present at the Cantor Global Healthcare Conference
|
